Analyst Price Target is $49.33
▲ +139.83% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Aerovate Therapeutics in the last 3 months. The average price target is $49.33, with a high forecast of $65.00 and a low forecast of $35.00. The average price target represents a 139.83% upside from the last price of $20.57.
Current Consensus is
Buy
The current consensus among 3 investment analysts is to buy stock in Aerovate Therapeutics. This Buy consensus rating has held steady for over two years.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Read More